Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") and Wenzhou KanryBio Biotech Co., Ltd.  ("KanryBio") announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and products for biomarker assay kits. By integrating Sanyou Bio's core strengths in innovative biologics discovery with KanryBio's expertise in kit product development and manufacturing, the collaboration aims to provide global biopharmaceutical R&D clients with more efficient, precise, and reliable total solutions for biomarker detection, thereby accelerating drug development and companion diagnostic processes.

Biomarkers are playing an increasingly critical role in drug R&D, clinical diagnostics, and personalized medicine. This strategic partnership is built upon both parties' deep understanding of industry trends and mutual recognition of each other's technical prowess. Sanyou Bio will leverage its globally leading AI Super-Trillion-Level (AI-STAL) intelligent molecular library and integrated drug discovery platform to drive innovative discovery and optimization of high-performance antibodies and other key reagents targeting specific biomarkers. KanryBio will contribute its extensive experience in high-end analytical instruments, high-value consumables, and kit development, along with its international-standard production and quality control systems, to ensure scalable manufacturing, performance validation, and stable supply of the co-developed products.

Through deep synergy, this collaboration aims to create core value across multiple dimensions:

•  Accelerated R&D Cycles: Joint development will shorten the timeline from discovery to productization of high-performance biomarker detection reagents, helping pharmaceutical companies expedite patient stratification, efficacy evaluation, and companion diagnostic development.
•  Enhanced Product Competitiveness: Combining Sanyou Bio's source innovation with KanryBio's engineering and cost-control capabilities, the partners will create high-end, domestically produced assay kits with superior performance, stable supply, and higher cost-effectiveness, reducing dependence on imported products in certain fields.
•  New Market Expansion: By pooling market resources, both companies will jointly promote the co-developed kit products and solutions, offering superior options to biopharmaceutical companies, CROs, and diagnostic firms worldwide and jointly exploring the vast precision medicine market.

Dr. Linglong Zou, Chairman and CEO of KanryBio, stated: "We are thrilled to partner with Sanyou Bio. Their exceptional capabilities in ultra-large-capacity molecular libraries and intelligent screening are impressive. This collaboration provides KanryBio with a powerful innovation engine for the 'upstream' of kit product development. We believe the deep integration of 'discovery + translation' will enable us to respond rapidly to market needs and develop high-quality biomarker detection products that address real customer pain points, jointly advancing industry technology."

Dr. Guojun Lang, Founder and CEO of Sanyou Bio, commented: "The collaboration with KanryBio is a significant extension of Sanyou Bio's mission—'to make innovative biologics accessible to all'—into the field of precision diagnostics. KanryBio's proven 'hard strength' in systematic kit development and production is widely recognized. This strategic synergy is a key step in connecting our molecular discovery capabilities with an industrial partner's engineering platform. We expect this partnership will not only supply high-quality key reagents but also enable us to participate in creating final products that solve customer detection challenges, providing more robust tools for biopharmaceutical R&D and jointly empowering the upgrade of the industry chain."

This strategic partnership marks a solid step for Sanyou Bio in deepening industrial collaboration and building core technological advantages. Both parties will use this collaboration as a starting point to continuously explore broader cooperation, striving to become trusted partners for global biopharmaceutical R&D enterprises.